Novartis AG (SWX:NOVN) entered into a definitive agreement to acquire Encore Vision, Inc. on December 20, 2016. The transaction is subject to customary closing conditions including regulatory approval. As on January 12, 2017, the transaction was approved by the Federal Trade Commission. Adam Golden, Michael Szlamkowicz, Andrew Felton, Scott Grossman, Jeff Jay, Scott Reisch, Marta Orpiszewska, Marta Steinman, Michael Applebaum, Adrienne Jack, Michael DeLarco, Elizabeth Seaver, Jeffrey Tolin, Catherine Chen, Robert Leibenluft, Leigh Oliver, Arlene Chow and Peter Noh of Hogan Lovells acted as legal advisors to Novartis. Christopher L. Kaufman, Josh Dubofsky, Saad Khanani, Alexander White and Kevin Tsai of Latham & Watkins LLP acted as legal advisors for Encore Vision, Inc. Piper Jaffray acted as a financial advisor to Encore Vision, Inc. in this transaction. Novartis AG (SWX:NOVN) completed the acquisition of Encore Vision, Inc. for approximately $460 million on January 20, 2017. As per terms of agreement, Novartis AG agreed to pay $366 million in cash and preliminary present value of contingent consideration of $90 million.